Back to Atlas
BSemi-durableStandard research/education caution
CMP-0676
Research chemical/reference listing
Ribupatide
Metabolic / fat loss
Appetite, glucose, weight, and metabolic regulation
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Incretin / metabolic peptide or small molecule
- Primary mechanism
- Incretin/amylin/glucagon-axis receptor modulation
- Primary market use
- Metabolic / fat loss
Pharmacology
- Molecular weight (Da)
- 4907.48
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~12 h–7 days depending analog/acylation
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 8 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Stackability
Commonly compared/stacked in metabolic and body-composition protocols; verify redundancy and risk.
Notes
Ribupatide TFA is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 ( GLP-1 ) receptor agonist. Ribupatide TFA can be studied in antidiabetic research.